Capricor Therapeutics, Inc. (CAPR): Total Assets
$355.95M
As of 2025-12-31
$368.74M
As of 2026-06-30
+92.2%
3-year compound annual growth
+59.4%
5-year compound annual growth
+36.3%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $355.95M | +108.8% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $170.48M | +190.3% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $58.73M | +17.2% | 2025-03-26, Balance as of period end |
| 2022-12-31 | $50.09M | +21.2% | 2024-03-11, Balance as of period end |
| 2021-12-31 | $41.33M | +19.4% | 2023-03-17, Balance as of period end |
| 2020-12-31 | $34.62M | +211.5% | 2022-03-11, Balance as of period end |
| 2019-12-31 | $11.11M | +20.2% | 2021-03-15, Balance as of period end |
| 2018-12-31 | $9.25M | -43.2% | 2020-03-27, Balance as of period end |
| 2017-12-31 | $16.27M | -13.2% | 2019-03-29, Balance as of period end |
| 2016-12-31 | $18.75M | +16.7% | 2018-03-22, Balance as of period end |
| 2015-12-31 | $16.07M | +17.9% | 2017-03-16, Balance as of period end |
| 2014-12-31 | $13.63M | +146.2% | 2016-03-30, Balance as of period end |
| 2013-12-31 | $5.54M | +2.1% | 2015-03-16, Balance as of period end |
| 2012-12-31 | $5.42M | +295.3% | 2014-03-31, Balance as of period end |
| 2011-12-31 | $1.37M | -62.6% | 2013-06-21, Balance as of period end |
| 2010-12-31 | $3.67M | n/a | 2012-04-02, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Capricor Therapeutics, Inc. (CAPR) | 2025-12-31 | $355.95M | +108.8% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $37.66M | -3.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $261.15M | +8.4% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
Compare CAPR, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗